amitosilveride B mesylate

Amitosilveride B mesylate is a small molecule antiplatelet agent developed by Nanjing Ke Feiping Shenghui Pharmaceutical. It functions as a reversible antagonist of the P2Y purinoceptor 12 (P2Y12), a key receptor involved in ADP-induced platelet activation and aggregation. By blocking this receptor, the drug inhibits thrombus formation, making it a candidate for the treatment of acute ischemic cerebrovascular diseases, such as acute ischemic stroke and transient ischemic attack (TIA). The drug is designed to provide rapid and reversible platelet inhibition, which may offer advantages in clinical settings where quick recovery of platelet function is necessary. It is currently in Phase 1 clinical development, with studies focusing on its safety, tolerability, and pharmacodynamic profile in healthy volunteers.

Other names

amitosilveride B甲磺酸阿米替西韦B